DexCom, Inc. $DXCM Shares Acquired by Tobam

Tobam increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 49,755 shares of the medical device company’s stock after acquiring an additional 3,514 shares during the quarter. DexCom makes up approximately 1.7% of Tobam’s holdings, making the stock its 22nd biggest holding. Tobam’s holdings in DexCom were worth $4,343,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Andra AP fonden purchased a new stake in DexCom in the 2nd quarter valued at about $26,000. Zions Bancorporation National Association UT acquired a new stake in shares of DexCom during the 1st quarter worth $27,000. Anderson Financial Strategies LLC purchased a new position in shares of DexCom in the 1st quarter worth $37,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in DexCom during the second quarter valued at about $45,000. Finally, Atlantic Union Bankshares Corp purchased a new position in shares of DexCom in the 2nd quarter worth about $70,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Trading Up 6.0%

Shares of DXCM stock opened at $58.13 on Wednesday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25. The company has a market cap of $22.67 billion, a PE ratio of 40.37, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average is $68.51 and its two-hundred day moving average is $77.51.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter last year, the company posted $0.45 earnings per share. DexCom’s quarterly revenue was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on DXCM. Raymond James Financial raised their price target on shares of DexCom from $99.00 to $102.00 and gave the company a “strong-buy” rating in a report on Thursday, July 31st. The Goldman Sachs Group dropped their price objective on shares of DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Truist Financial restated a “buy” rating and set a $82.00 target price (down previously from $94.00) on shares of DexCom in a report on Monday, November 3rd. UBS Group decreased their target price on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, November 3rd. Finally, Stifel Nicolaus began coverage on shares of DexCom in a report on Tuesday, October 21st. They set a “buy” rating and a $85.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $87.62.

Insider Buying and Selling at DexCom

In other DexCom news, Director Kyle Malady sold 667 shares of the stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares in the company, valued at $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach acquired 18,200 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was acquired at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the transaction, the chief operating officer directly owned 331,697 shares in the company, valued at $18,256,602.88. This trade represents a 5.81% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 9,331 shares of company stock worth $652,085 in the last 90 days. 0.32% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.